Tonix Pharmaceuticals Reports Positive Phase 1 Data for TNX-1500 Anti-CD40L Antibody in Transplant Rejection Prevention
核心洞察
Tonix Pharmaceuticals (搜索) published Phase 1 clinical data for TNX-1500, a third-generation anti-CD40L (搜索) monoclonal antibody designed to prevent kidney transplant rejection (搜索), in the Journal of Clinical Immunology.
The study demonstrated that TNX-1500 was generally well tolerated with no serious adverse events and effectively blocked T cell-dependent antibody responses at all tested doses in 26 healthy volunteers.
TNX-1500 showed a favorable pharmacokinetic profile with half-lives of 33.8-37.8 days supporting monthly dosing, and a Phase 2 study at Massachusetts General Hospital is planned for the second half of 2026.
Tonix Pharmaceuticals (搜索) has published positive Phase 1 clinical data for TNX-1500, an investigational third-generation anti-CD40L (搜索) monoclonal antibody being developed for kidney transplant rejection (搜索) prevention. The results, published in the peer-reviewed Journal of Clinical Immunology, demonstrate the drug's favorable safety profile and immunosuppressive activity in healthy volunteers.
Study Design and Results
The first-in-human Phase 1 study was a single-center, randomized, double-blind, placebo-controlled, single-ascending dose escalation trial involving 26 healthy adult volunteers. Participants received single intravenous infusions of TNX-1500 at doses of 3, 10, or 30 mg/kg, or placebo, followed by keyhole limpet hemocyanin (KLH) antigen injections on days 2 and 29 to assess T cell-dependent antibody responses (TDARs). The study monitored participants over a 120-day follow-up period.
TNX-1500 demonstrated dose-dependent immunosuppressive activity, blocking the primary T cell-dependent antibody response to KLH at all tested doses. At the 10 and 30 mg/kg doses, the drug blocked both primary and secondary responses, while the 3 mg/kg dose reduced the peak secondary response by approximately 70% relative to placebo.
Safety and Tolerability Profile
The safety profile was favorable, with no serious adverse events reported and no study discontinuations due to adverse events. The only treatment-emergent adverse event possibly related to TNX-1500 was aphthous ulcer, occurring in one participant in each of the three dose groups. All adverse events were rated as mild and resolved within 2-10 days. Notably, there were no administration or injection site reactions, which had been prespecified as adverse events of special interest.
Pharmacokinetic Characteristics
Pharmacokinetic analyses revealed approximately dose-proportional exposure across the 3 to 30 mg/kg range. Mean terminal elimination half-lives were 37.8 days at the 10 mg/kg dose and 33.8 days at the 30 mg/kg dose, supporting monthly intravenous dosing. TNX-1500 was associated with rapid (less than one hour post-dose) and sustained reduction in soluble CD40L (搜索) over the entire 120-day study period.
Clinical Development Strategy
"The CD40L (搜索) is a validated target for preventing organ rejection in transplant and treating autoimmune disease, yet no anti-CD40L mAb has been approved for any indication," said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals (搜索). "TNX-1500 is a Phase 2 ready humanized mAb engineered to improve safety and tolerability relative to first-generation anti-CD40L mAbs, while preserving the durable half-life and certain effector functions associated with the Fc or crystallizable fragment."
Dr. Gregory Sullivan, M.D., Chief Medical Officer of Tonix Pharmaceuticals (搜索), noted that TNX-1500 "demonstrated a favorable safety profile, suppressed the primary and secondary T cell-dependent antibody responses to keyhole limpet hemocyanin antigen, and showed a half-life which supports monthly intravenous dosing."
Next Steps in Development
A Phase 2 investigator-initiated study at Massachusetts General Hospital (MGH) is expected to begin in the second half of 2026, pending FDA clearance of the Investigational New Drug application. The study will evaluate TNX-1500 in five kidney transplant recipients, assessing safety, tolerability, and activity in preventing kidney transplant rejection (搜索) while potentially reducing exposure to conventional immunosuppressive drugs.
The upcoming Phase 2 study aims to address limitations of current immunosuppressive therapies, which are associated with infection, cancer, cardiovascular side effects, and various metabolic derangements with long-term use. Ongoing collaborations with MGH include research on allo-heart and kidney transplantation in nonhuman primates, prevention of xenograft rejection, and prevention of allograft rejection in sensitized patients.
TNX-1500 represents a third-generation approach to CD40L (搜索) inhibition, designed as an Fc-modified humanized IgG4 monoclonal antibody that targets CD40L (also known as CD154 (搜索)). The drug is being developed not only for organ transplant rejection prevention but also for treatment of autoimmune diseases (搜索), representing multiple potential therapeutic applications beyond solid organ and bone marrow transplantation.